Inlyta

opdivo

Opdivo falls short at NICE, thanks to Inlyta discount

England’s cost-effectiveness watchdogs have a love-hate relationship with Opdivo, the hot Bristol-Myers cancer treatment. A new Opdivo cocktail recently won a quick thumbs up in melanoma from NICE’s influential gatekeepers, but now they've stiff-armed the drug in kidney cancer.
pfe

Pfizer cancer chief touts up-and-coming portfolio

Does Pfizer deserve more credit for its up-and-coming cancer portfolio? You bet, global oncology chief Liz Barrett said Monday, pointing past fast-growing Ibrance to kidney cancer therapy Inlyta and its immunotherapy hopefuls.